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Introduction
Adiposopathy (‘‘sick fat’’) is deﬁned as pathogenic
adipose tissue that is promoted by positive caloric
balance, increased energy storage and sedentary life-
style in genetically and environmentally susceptible
patients (1). Impaired adipocyte proliferation or dif-
ferentiation (adipogenesis), visceral adiposity, growth
of adipose tissue beyond adequate vascular supply
and ectopic fat deposition are anatomical manifesta-
tions of adiposopathy that are associated with
adverse endocrine and immune responses leading to
metabolic disease (2,3).
Adipose tissue is an active endocrine organ (4–6)
and an active immune organ (7,8). Its functionality
is important for metabolic health. During positive
caloric balance, the manner in which energy is stored
correlates to the risk of developing metabolic disease.
For example, adipogenesis is a biological process
involving proliferation of preadipocytes from precur-
sor cells, and then their differentiation into mature
adipocytes. Adipocytes and adipose tissue express a
number of factors that directly inﬂuence adipogenesis
(such as modulating and transcription factors) as
well as factors that indirectly inﬂuence adipogenesis
(such as those that affect angiogenesis, as well as the
dissolution and reformation of adipose tissue extra-
cellular matrix) (9). It is the unencumbered ability of
adipocytes to proliferate and differentiate during
positive caloric balance that prevents adipocyte dys-
function. This is clinically important because
impaired adipocyte proliferation (resulting in exces-
sive fat cell enlargement) and impaired adipocyte dif-
ferentiation may both cause adipocyte dysfunction,
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Objective: To review how bariatric surgery in obese patients may effectively treat
adiposopathy (pathogenic adipose tissue or ‘sick fat’), and to provide clinicians a
rationale as to why bariatric surgery is a potential treatment option for overweight
patients with type 2 diabetes, hypertension, and dyslipidaemia. Methods: A group
of clinicians, researchers, and surgeons, all with a background in treating obesity
and the adverse metabolic consequences of excessive body fat, reviewed the medi-
cal literature regarding the improvement in metabolic disease with bariatric sur-
gery. Results: Bariatric surgery improves metabolic disease through multiple, likely
interrelated mechanisms including: (i) initial acute fasting and diminished caloric
intake inherent with many gastrointestinal surgical procedures; (ii) favourable alter-
ations in gastrointestinal endocrine and immune responses, especially with bariatric
surgeries that reroute nutrient gastrointestinal delivery such as gastric bypass pro-
cedures; and (iii) a decrease in adipose tissue mass. Regarding adipose tissue
mass, during positive caloric balance, impaired adipogenesis (resulting in limita-
tions in adipocyte number or size) and visceral adiposity are anatomic manifesta-
tions of pathogenic adipose tissue (adiposopathy). This may cause adverse adipose
tissue endocrine and immune responses that lead to metabolic disease. A decrease
in adipocyte size and decrease in visceral adiposity, as often occurs with bariatric
surgery, may effectively improve adiposopathy, and thus effectively treat metabolic
disease. It is the relationship between bariatric surgery and its effects upon patho-
genic adipose tissue that is the focus of this discussion. Conclusions: In selective
obese patients with metabolic disease who are refractory to medical management,
adiposopathy is a surgical disease.
What’s known
Bariatric surgery is indicated to treat obese
patients, especially those with comorbidities.
What’s new
Bariatric surgery is not only effective in reducing fat
mass, but also effective in improving many
metabolic diseases associated with obesity through
correction of adiposopathy (‘‘sick fat’’) as well as
possibly through mechanisms independent of its
effects upon adipose tissue.
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For example, if storage of fats in adipose tissue is
impaired during positive caloric balance due to
inadequate adipogenesis, then this may result in an
‘overﬂow’ of lipid and free fatty acids (10). Increases
in circulating free fatty acids may be ‘lipotoxic’ to
various organs, which contribute to metabolic disease
(10). Thus, adipogenic factors produced by adipo-
cytes⁄adipose tissue (as well as other body organs)
are an important determinant of whether an increase
in adipose tissue simply increases the risk of adipose
tissue mass pathology, or increases the risk of adi-
pose tissue metabolic pathology as well.
Previously, a group of clinicians and researchers,
each with a background in endocrinology, assembled
together and reached a consensus that: Adiposopathy
(‘‘sick fat’’) is an endocrine disease (11). This reﬂected
the recognition that pathogenic adipose tissue can
‘cause’ and⁄or worsen metabolic disease. From a
clinical standpoint, it is equally relevant that thera-
peutic interventions that reduce adipose tissue’s
adverse endocrine and immune responses may ‘cure’
or improve metabolic disease (12,13).
Examples of interventions that may improve the
adverse metabolic consequences of adiposopathy
include appropriate nutrition, increased physical
activity and pharmaceuticals (12). Bariatric surgery
in obese patients is also an intervention that reduces
body fat and effectively treats type 2 diabetes mellitus
(T2DM) (14–16), hypertension (14,16) and dys-
lipidaemia (16). Current evidence supports that the
improvement in metabolic diseases with bariatric
surgery is largely through reversing the otherwise
pathogenic adipose tissue endocrine and immune
responses associated with pathogenic adipose tissue.
The efﬁcacy of bariatric surgery on metabolic disease
can be dramatic with 30–60% ‘resolution’ of high
blood pressure (17,18) and 70% improvement in
dyslipidaemia (18). Most notable is the remission of
T2DM with bariatric surgery, which is reported to
occur as high as 80% with gastric bypass (17,18).
This follow-up adiposopathy consensus paper
reviews the effects of bariatric surgery on adipose tis-
sue pathophysiology, as well as its therapeutic effects
upon metabolic diseases often associated with ‘sick
fat’.
Surgical treatments for adiposopathy
Historically, surgical obesity treatments have utilised
a variety of techniques (19). Currently, the most
common bariatric surgeries include gastric bypass
and laparoscopic adjustable gastric banding (LAGB).
These different surgical procedures may produce dif-
ferent metabolic results.
Gastric bypass
Gastric bypass, through the creation of a Roux-en-Y
anastomosis, was named after Cesar Roux, a Swiss sur-
geon. The Roux-en-Y surgery was originally per-
formed in 1892 for the intent of ‘bypassing’ the
stomach to treat antral or pyloric obstruction (20).
Since the 1950s and 1960s, the gastric bypass proce-
dure has evolved as a treatment for obesity (21,22). It
commonly involves creation of a small (20–30 cc)
proximal stomach pouch, attached to the distal end of
the oesophagus. This is achieved by stapling the proxi-
mal stomach, and then surgically dividing the parti-
tioned gastric pouch from the rest of the stomach. The
next step is the division of the jejunal portion of the
small intestine into a jejunal proximal limb (which
maintains its attachment to the duodenum), and a
jejunal distal ‘Roux limb,’ which is then connected
(anastomosis) to the newly created stomach pouch
(gastrojejunostomy) (19). Finally, the residual proxi-
mal jejunal limb (attached to the duodenum and
stomach) undergoes anastomosis at a variable distance
distal from the jejunal division. This jejunojejunostomy
completes the ‘Y’ conﬁguration. With this procedure,
ingested nutrients pass directly from the gastric pouch
into the jejunal Roux limb of the jejunum. Gastric, pan-
creatic and biliary ﬂuids continue to drain through the
residual jejunal proximal limb that remains attached to
the duodenum⁄stomach, which then empties into a
more distal jejunal location. Thus, ingested nutrients
‘bypass’ most of the stomach, and ‘bypass’ all of the
duodenum and proximal jejunum, resulting in more
distal digestion.
The length of each limb may vary according to
surgical technique and preference. With a standard
gastric bypass procedure (sometimes termed proxi-
mal gastric bypass), the risk of malabsorption of
macronutrients is minimal. However, with a distal
gastric bypass procedure, the jejunal severing is more
distal from the stomach. Less small intestine then
remains in the roux limb and more of the jejunum
is bypassed. While some reports suggest that proxi-
mal vs. distal gastric bypass do not differ with regard
to efﬁcacy and complications (23), it is the experi-
ence of others that distal gastric bypass may result in
greater weight loss. However, it may also increase the
risk of macronutrient malabsorption. Thus, it is
unclear if the potential, yet un-established beneﬁts of
additional weight loss from distal gastric bypass pro-
cedures warrant the increased potential metabolic
risks of malabsorption. As such, some surgeons are
very selective about choosing to perform the distal
gastric bypass procedure, with others preferring not
to perform this type of procedure at all (24).
Gastric bypass has several potential mechanisms
accounting for its efﬁcacy. The small size of the
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of food intake, and alters endocrine and neural sig-
nalling of appetite and satiety. As noted above,
depending upon the surgical technique, malabsorp-
tion of macronutrients may sometimes contribute to
weight loss efﬁcacy, particularly with the less com-
monly used distal gastric bypass procedure. Regard-
ing micronutrients, malabsorption can occur with
any gastric bypass procedure, and may result in
nutritional deﬁciencies (Table 1). Finally a ‘dumping
syndrome’ (25) may occur, which is caused by rapid
expansion of the jejunum with hyperosmolar food.
Dumping syndrome is clinically manifest by nausea,
vomiting, bloating, cramping, diarrhoea and fatigue
immediately after a meal or as long as 3 h after a
meal.
Laparoscopic adjustable gastric banding (LAGB)
In the 1970s, non-adjustable banding around the
upper part of the stomach emerged as a bariatric
surgical procedure (26). In the early 1980s, adjustable
gastric bands were developed, and in the 1990’s,
underwent more widespread clinical use. With this
procedure, a silicone band is laparoscopically placed
around a proximal portion of the stomach. The band
diameter can be adjusted. No division or anastomosis
of the intestine is involved. If the band is too tight,
the transit of food from the oesophagus and proxi-
mal stomach into the rest of the stomach may be
impaired, potentially resulting in the unintended
complication of postprandial vomiting and need for
gastric band adjustment. However, while LAGB is
often described as a ‘restrictive’ procedure (with gas-
tric bypass also having a ‘restrictive’ component)
(27) (Table 1), the weight loss efﬁcacy of this
‘restrictive’ procedure, in most cases, may not be due
to delayed nutrient ﬂow. Gastric emptying does not
appear to be altered by LAGB (28). Some suggest
that the predominant mechanisms accounting for
LAGB weight loss efﬁcacy are increased satiety (29)
and decreased hunger (30).
Effects of bariatric surgery upon
adiposopathy
Adipose tissue anatomical changes with
bariatric surgery
It may be intuitive to expect that the greatest long-
term effects of bariatric surgery upon adiposopathy
would be related to effects upon adipose tissue anat-
omy and physiology. When bariatric surgery results
in weight loss in patients with excessive fat-related
metabolic disease, a reduction in adipocyte size (31)
and a reduction in visceral adiposity (32) would both
be expected to result in improvements in adipose
tissue endocrine and immune responses. Thus, by
favourably altering adipose tissue anatomy from both
a cellular and organ standpoint, bariatric surgery
improves metabolic disease (9,13,33).
On a cellular level, excessive adipocyte hypertrophy
leads to fat cell dysfunction that might be character-
ised as representing ‘sick fat’ (1). The ‘sick fat’ associ-
ated with excessive fat cell enlargement represents a
‘stress condition’ for intracellular organelles such as
the endoplasmic reticulum (34), which can lead to
inﬂammation, insulin resistance, limitations on energy
storage, net increase in circulating free fatty acids
(35), lipotoxicity (10), and adverse endocrine and
immune responses. All of these pathogenic adipose
tissue effects contribute to metabolic diseases such as
T2DM (2,9). On an organ level, adipose tissue growth
beyond its vascular supply is an anatomical manifesta-
tion of adiposopathy that may result in hypoxia (9).
Hypoxia promotes inﬂammatory responses that are
increasingly being recognised as a potential contribu-
tor to metabolic disease (3,36,37). Some authors have
suggested that hypoxia may underlie the inﬂammatory
response in adipose tissue (38). Thus, a reduction in fat
cell size and reduction in adipose tissue growth
beyond its vascular supply are favourable effects that
at least partially explain the observed reduction in
inﬂammatory markers with a reduction in adiposity,
as occurs with bariatric surgery.
Another anatomical ﬁnding with bariatric surgery
is a reduction in hepatic fat (steatosis) (39,40), with
the possible exception of those who lose weight very
rapidly (41). Reduced hepatic steatosis with bariatric
surgery is an anatomic ﬁnding that may reﬂect a
decrease in free fatty acid delivery to the liver (as a
result of improved ability of adipose tissue to store
circulating free fatty acids) and a diminished poten-
tial for lipotoxicity (10). As with other anatomic
ﬁndings with fat weight loss, a reduction in hepato-
steatosis may be associated with an improvement in
metabolic disease (9,13).
Bariatric surgery and the six faces
of adiposopathy
Pathophysiologically, adiposopathy has at least six
‘faces’ that contribute to metabolic disease (13).
Brieﬂy, bariatric surgery may affect these biological
processes in the following ways:
(1) Impaired adipogenesis: Adipogenesis is a bio-
logical process necessary for optimal storage of excess
energy during positive caloric balance. Energy storage
(a critical function of adipose tissue) is dependent
upon adipocyte number and size (3), and is deter-
mined by the proliferation of precursor cells in to
preadipocytes, which then undergo differentiation
into mature adipocytes (42). During positive caloric
Adiposopathy and bariatric surgery 1287
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LAGB Gastric bypass
Common characterisation of
procedure
Restrictive* Multimechanistic
Weight loss (mean) Gastric bypass > LAGB (20–30 kg) Gastric bypass > LAGB (30–40 kg)
Improvement of
obesity-related comorbidities
Gastric bypass > LAGB Gastric bypass > LAGB
Short-term morbidity Gastric bypass > LAGB Gastric bypass > LAGB
Perioperative mortality (131) Gastric bypass > LAGB Gastric bypass > LAGB
Reoperation and readmission Variable (5–10%) Variable (5–10%)
Days of hospitalisation for
procedure
1 Day or less for procedure, if no
complications
2–4 Days for open procedure
Able to be performed
laparoscopically
Yes Yes
Permanent alterations in
gastrointestinal tract
No, band may be adjusted or
removed
Yes, although ‘reversal’ reoperation can be performed
Loss of fat-free mass (132) Gastric bypass > LAGB Gastric bypass > LAGB
2008 Initial cost estimate $17,000 $26,000
Acute complications Band too tight with
gastrointestinal
obstructive symptoms
Haemorrhage
Gastrointestinal bleeding
Infection
Cardiac dysrhythmias
Atelectasis and pneumonia
Deep vein thrombosis
Gastrointestinal obstruction
Haemorrhage
Gastrointestinal bleeding
Anastomotic leaks
Infection
Cardiac dysrhythmias
Atelectasis and pneumonia
Deep vein thrombosis
Pulmonary emboli
Rhabdomyolysis
Chronic complications (22) Band slippage, erosion, port infection,
disconnection and displacement
Oesophageal dilation
Rare nutrient deﬁciencies if persistent
vomiting or marked and sustained
decrease in nutritional intake
Unclear effects on
depression
(133,134)
Marginal ulcers
Oesophageal dilation
Dumping syndrome with reactive hypoglycaemia
Small bowel obstruction caused by internal hernias
or adhesions
Anastomotic stenoses (stomal narrowing)
Gallstones
Calcium deﬁciency
Secondary hyperparathyroidism
Iron deﬁciency
Protein malnutrition
Other nutritional and mineral deﬁciencies (e.g. deﬁciencies of
vitamins A, C, D, E, B, and K, folate, zinc, magnesium,
thiamine, etc.) (135)
Anaemia (often related to mineral and nutrition deﬁciencies)
Metabolic acidosis
Bacterial overgrowth
Kidney stones (oxalosis)
Neuropathies (resulting from nutritional deﬁciencies)
Osteoporosis (often caused by calcium deﬁciency and
chronically elevated parathyroid hormone levels)
Improvement or worsening of depression (133,136)
Need for long-term follow-up LAGB = Gastric bypass LAGB = Gastric bypass
*While often characterised as a ‘restrictive’ procedure, macronutrient transit may not be delayed with LAGB, and the weight loss effects may be the result of
increased satiety and decreased hunger (see text).
The Roux-en-Y gastric procedure has a combination of both restrictive and malabsorptive elements (23,27), and thus its mechanisms of weight loss ad metabolic
efﬁcacy are complex.
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pogenesis, then the patient may not manifest meta-
bolic disease, even with fat weight gain. Conversely,
if fat cell proliferation is inadequate during positive
caloric balance, then excessive adipocyte hypertrophy
may ensue, which is associated with pathogenic
endocrine and immune responses that contribute to
metabolic diseases (9). If fat cell differentiation is
impaired, then adipocyte storage of energy may also
be impaired, resulting in pathogenic adipose tissue
responses as well (43).
Data are relatively scarce regarding the effect of
bariatric surgery upon the numerous adipose tissue
and non-adipose tissue adipogenic factors (e.g. those
involved with adipocyte modulation and transcrip-
tion, extracellular matrix formation, angiogenesis,
etc.) (9). Ghrelin (derived from ‘gh’ for growth hor-
mone and ‘relin’ for release) is an orexigenic peptide
hormone whose secretion increases before meals, and
decreases after meals. In addition to stimulating the
central growth-hormone secretagogue receptor 1a
(44), ghrelin may also stimulate cell proliferation and
inhibit preadipocyte differentiation (45). Because it
originates from the stomach, ghrelin may be an
important hormone inﬂuenced by bariatric surgery.
However, the reported effects of bariatric surgery
upon ghrelin levels are inconsistent, with at least one
study suggesting that fasting ghrelin is inversely
related to body mass index (BMI), with no apparent
independent effect of gastric bypass on ghrelin levels
beyond weight loss alone (46). Therefore, it is as yet
unclear that ghrelin levels alone provide clinically
meaningful information, such as predicting weight
loss in patients undergoing bariatric surgery (47).
Adiponectin is an anti-inﬂammatory protein
secreted from adipocytes whose secretion is often
decreased with obesity, insulin resistance and T2DM
(2). Adiponectin may promote cell proliferation and
differentiation of preadipocytes into adipocytes (48).
Bariatric surgery resulting in weight loss is associated
with increased adiponectin levels (49).
Another example of an adipogenic marker that
may be altered with bariatric surgery is acylation-
stimulating protein, which enhances short-term
energy clearance and fat storage through increasing
triglyceride (TG) synthesis in fat cells (2). This lipo-
genic adipocyte protein increases with adipocyte dif-
ferentiation and decreases after bariatric surgery (50).
Although data such as these are limited, some pre-
liminary hypotheses might reasonably be made based
upon the above. During weight loss, the ability or
capacity for adipogenesis may or may not be
increased with weight loss (51), and some pro-adipo-
genic adipoctye factors may actually increase. How-
ever, as long as weight loss is ongoing, the net fat
cell proliferation signalling may be decreased; lipo-
genic factors may be decreased as well. A decrease in
adipogenic markers with bariatric surgery may be a
normal physiological response to the reduced caloric
balance after bariatric surgery; because with less calo-
ric intake, less adipogenic signalling is required for
energy storage. This would help explain why fat cell
number is decreased in patients losing weight after
bariatric surgery (52). Other data also support that a
decrease in adipogenesis with weight loss may be
physiological, and not pathophysiological. For exam-
ple, bariatric surgery may improve metabolic markers
such as insulin and adiponectin, while simulta-
neously decreasing adipogenic markers such as
vascular endothelial growth factor-A (53).
(2) Increased pathogenic responses of adipose tissue
storage depots most described to promote metabolic
disease: While hypertrophy of multiple adipocyte
depots may contribute to metabolic disease, visceral
fat is among the most metabolically active adipose
tissue depots (9). Visceral fat is the best described
depot wherein an increase in its mass results in
pathogenic adipose tissue endocrine and immune
responses. Visceral adiposity is associated with an
increased release of pathogenic factors into the portal
circulation leading directly to the liver (13). Thus, vis-
ceral adiposity contributes to hepatic-mediated meta-
bolic diseases, such as T2DM and dyslipidaemia (9).
Through a global reduction in adiposity, bariatric
surgery reduces visceral adipose tissue (32), which
may help to account for its efﬁcacy in reducing the
metabolic disease.
(3) Increased circulating free fatty acids: A net
increase in circulating free fatty acids occurs when
adipocyte lipolysis exceeds adipocyte lipogenesis, as
occurs with adiposopathy (9). Increased circulating
free fatty acids may contribute to lipotoxicity (10) as
well as fatty liver (hepatosteatosis). However, not all
free fatty acids contribute to lipotoxicity (54) (e.g.
polyunsaturated fatty acids such as omega-3 fatty
acids) (55). It is also unclear if increased hepatic TG
content, so often found in overweight patients with
metabolic disease, is simply a marker for increased
free fatty acid delivery to the liver, or if hepatic TGs
themselves actively participate in creating derange-
ments leading to metabolic disease. What does seem
to be clear is that an increase in circulating saturated
free fatty acids increases the ﬂux of free fatty acid to
body organs. This may result in lipotoxicity to the
liver (causing insulin resistance and increased hepatic
glucose output), pancreas (causing impaired beta cell
function with relative insulinopenia) and muscle
(with the accumulation of intramyocellular lipids,
such as diacylglycerol, fatty acyl CoA and ceramides
also contributing to insulin resistance) (3,9,10).
Adiposopathy and bariatric surgery 1289
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weight loss, as might occur with bariatric procedures
associated with signiﬁcant malabsorption. If so, then
similar to periods of starvation or during administra-
tion of very low calorie diets (56), free fatty acids
may initially be increased for the ﬁrst month or so,
as result of rapid lipid mobilisation from fat depots
(57). However, presumably after stabilisation of fat
weight loss, circulating free fatty acids decrease
(58,59). A reduction in circulating free fatty acids
may contribute to the reduction in metabolic disease
after bariatric surgery.
(4) Pathogenic adipose tissue endocrine responses:
An increase in body fat, particularly when associated
with adipocyte hypertrophy and visceral adiposity,
causes pathogenic adipose tissue endocrine responses
that contribute to metabolic diseases (3). The mecha-
nisms by which these endocrine abnormalities con-
tribute to metabolic disease are beyond the scope of
this discussion (2,9). However, Table 2 shows the
reported effects of pharmaceutical and surgical inter-
ventions upon adipose tissue endocrine factors that
are among the most commonly described to contrib-
ute to T2DM, hypertension and dyslipidaemia.
(5) Pathogenic adipose tissue immune responses:A n
increase in adipocyte hypertrophy and visceral adi-
posity causes pathogenic adipose tissue immune
responses that contribute to metabolic diseases (3).
The mechanisms by which adiposopathic immune
abnormalities contribute to metabolic disease are
beyond the scope of this discussion (2,9). However,
Table 2 shows the reported effects of pharmaceutical
and surgical interventions upon immune factors that
are among the most commonly described to contrib-
ute to T2DM, hypertension and dyslipidaemia.
Bariatric surgery may also have unique immuno-
logical considerations, compared with other thera-
peutic interventions. The more invasive the surgical
procedure, and the more need for subsequent
healing, then the greater the expected degree of pro-
inﬂammatory markers following bariatric surgery. A
subsequent reduction of inﬂammatory markers,
many of which also originate from pathogenic
adipose tissue, may take as long as 3–6 months after
bariatric surgery (33,60). Even with consideration of
gastric bypass alone, the systemic ‘stress’ and
immune response may depend on how the procedure
is performed. For example, the pro-inﬂammatory
Table 2 Examples of treatments for adiposopathy and their effects upon illustrative and selected adipose tissue factors that may contribute to
metabolic disease (11–13). Medical and surgical therapies that treat adiposopathy result in improvement in multiple adipose tissues metabolic
parameters, which helps explain why these same treatments improve T2DM, hypertension and dyslipidaemia
Intervention
May affect glucose metabolism,
blood pressure and lipid metabolism
May affect glucose
metabolism
May affect blood
pressure
May affect lipid
metabolism
Visceral
adipose
tissue
Free
fatty
acids Leptin Adiponectin
Tumour
necrosis
factor-a
Renin–
angiotensin–
aldosterone
enzymes Androgens Oestrogens
Nutrition and
physical activity
ﬂﬂ ﬂ › ﬂ ﬂ ﬂ (women)
› (men)
ﬂ⁄– (men)
PPAR-c *agonists
(pioglitazone,
rosiglitazone)
ﬂ⁄– ﬂﬂ ⁄ – ›ﬂ – ﬂﬂ ⁄ – (men)
Orlistat ﬂﬂ ﬂ › ﬂ ? ﬂ (women) ?
Sibutramine ﬂﬂ ﬂ › ⁄ –? ? ﬂ (women) ?
Cannabinoid receptor
antagonists
ﬂﬂ ﬂ › ﬂ ?? ?
LAGB§ ﬂ (137) ? ﬂ(29) ›(138) ﬂ (60) (130) ? ? ?
Gastric bypass§ ﬂ (139) ﬂ (59)– ﬂ(33) ›(140) ﬂ (140) (130) ﬂ (141) › (men) (142) ﬂ (men) (142)
›, increased; ﬂ, decreased; ?, unreported; –, neutral effect. LAGB, laparoscopic adjustable gastric banding; PPAR-c, peroxisome proliferator–activated receptor-c;
T2DM, type 2 diabetes mellitus. *PPAR gamma agents may: (i) increase adipose tissue proliferation and differentiation, (ii) favourably alter the visceral to subcutane-
ous adipose tissue deposition ratio, (iii) reduce hepatic fat deposition, and (iv) have improve other aspects of adipose tissue function (10,12,13). While some of the
weight gain associated with PPAR gamma agents results from ﬂuid retention, much of the weight gain observed with these agents used to treat metabolic diseases
traditionally associated with fat weight gain, paradoxically results from promoting increased amounts of functional adipose tissue. Not available in US. §Less weight
loss with LABG, compared with gastric bypass, may be associated with less pronounced improvements in inﬂammatory markers (130).–Acutely, (e.g. 1 month) free
fatty acids may be increased (see text).
1290 Adiposopathy and bariatric surgery
ª 2009 The Authors
Journal compilation ª 2009 Blackwell Publishing Ltd Int J Clin Pract, September 2009, 63, 9, 1285–1300response from an open gastric bypass may be greater
than with a laparoscopic gastric bypass, suggesting
that the open procedure has a greater degree of oper-
ative injury (61). Nonetheless, after the transient
increase in inﬂammatory markers have abated over
time, signiﬁcant and sustained weight reduction may
be required to reduce long-term pathogenic adipose
tissue inﬂammatory responses, which may otherwise
contribute to metabolic disease (2).
(6) Pathogenic interactions or ‘cross-talk’ with other
body organs: The promotion of metabolic disease
associated with adiposopathy is substantially depen-
dent upon the interaction or ‘cross-talk’ with multi-
ple other body organs, such as the nervous system,
immune system, skeletal muscle, cardiovascular sys-
tem, liver, gastrointestinal system, adrenal cortex and
thyroid (9). In patients with metabolic impairments
of other body organs, even mild to moderate patho-
genic adipose tissue endocrine and immune
responses may overwhelm the ability of these other
organs to compensate, which then contributes to
metabolic disease (9). Conversely, in patients without
impairment in other body organs, even if excessive
body weight persists after bariatric surgery, the path-
ogenic responses associated with adiposopathy may
become reduced to levels that are ‘manageable’ by
other body organs (62).
Mechanisms of improvement in
metabolic disease with bariatric
surgery beyond weight loss
Bariatric surgery has potential mechanisms indepen-
dent of fat weight loss that may improve metabolic
disease. Gastrointestinal surgery, such as bariatric sur-
gery, requires acute fasting, which results in metabolic
effects that may improve metabolic disease. Acute
withdrawal of caloric intake (such as through fast-
ing⁄starvation) may actually worsen insulin sensitivity
and glucose tolerance in lean and obese individuals
with and without T2DM, for at least as long as 60 h.
However, as with any dramatic reduction in caloric
intake in patients with diabetes mellitus,
hypoglycaemic medications must be withheld or
reduced to avoid the risk of hypoglycaemia before
and immediately after bariatric surgery. Thus, if the
procedure of fasting in the short, peri-operative phase
results in less need for anti-diabetes mellitus drug
treatment and if a reduction in the need of anti-dia-
betes mellitus drug treatment is considered a marker
for improved glucose metabolism, then acute, short-
term pre, peri and postoperative fasting might be
argued as an illustrative example by which bariatric
surgery might acutely improve metabolic disease.
Similarly, acute fasting may also result in short-term
(< 1 week) increased circulating lipids such as
cholesterol and TG levels (63). Conversely, because of
the lack of caloric intake, postprandial gastrointestinal
lipid absorption does not occur, and thus postpran-
dial lipaemia is reduced. Regarding blood pressure,
water-only fasting may reduce blood pressure in
hypertensive patients (64). Given all the above, the
effects of peri-operative fasting on metabolic disease
parameters might best be considered to be mixed.
However, it is unlikely that acute peri-operative fast-
ing signiﬁcantly contributes to the longer-term effects
of bariatric surgery upon metabolic disease.
Another manner in which bariatric surgery might
favourably affect metabolic disease (and obesity itself)
(65) is through altering an array of endocrine and
immune responses from the gastrointestinal tract
(66,67). As with adipose tissue, the gastrointestinal
system is an active endocrine and immune organ. It is
through the alteration in the secretion of gastrointesti-
nal hormones that has led some to postulate that
T2DM may be a surgical disease (68). Examples of
proposed mechanisms as to how bariatric surgery may
contribute to weight loss and improve metabolic dis-
ease beyond its favourable effects on adipose tissue
include: (i) the ‘lower intestinal hypothesis,’ wherein
rapid delivery of nutrients to the distal bowel enhances
the secretion of incretins such as glucagon-like peptide
and glucose-dependent insulinotropic peptide (i.e.
gastric inhibitory peptide) (69–72) as well as non-in-
cretin peptides such as Peptide YY (27) and (ii) the
‘foregut exclusion theory’ wherein bypassing the duo-
denum and proximal jejunum results in putative sig-
nalling favourable to glucose metabolism (27,73).
However, not all data support that improvements in
metabolic disease (or even weight loss) are caused by
the alterations in gastrointestinal tract hormone and
immune alterations found with bariatric surgery
(74,75). Furthermore, while it is unclear the extent to
which these gastrointestinal endocrine and immune
responses contribute to improvement in glucose sensi-
tivity and pancreatic beta cell function, it does appear
that caloric restriction and weight loss are the domi-
nant mechanisms by which bariatric surgery improves
overall glucose metabolism (76).
Responses to challenges and claims
regarding bariatric surgery as a
treatment for metabolic diseases
Based upon the authors’ experiences in prior publi-
cation efforts, review of the medical literature, as well
as discussions at scientiﬁc meetings and expert con-
ferences, the following claims listed below are among
the more common challenges to bariatric surgery as
a treatment for metabolic disease.
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published scientiﬁc information warranting
its use
Claim: Not enough is known about the metabolic
effects of current bariatric procedures, and thus not
enough is known about potential mechanisms of
action as to why bariatric surgery may improve met-
abolic disease.
Response: It is true that some of the more com-
mon bariatric surgery procedures, such as LAGB,
have limited published data on some of the more
commonly measured adipose tissue endocrine and
immune markers thought to contribute to metabolic
disease (Table 2). But more important than the need
to better understand the intricate mechanisms as to
why bariatric surgery has potential health beneﬁts is
the need to know that it does have potential health
beneﬁts for obese patients with metabolic disease.
The facts are that weight gain is clearly associated
with an increased risk of metabolic disease (2,62,77),
and that the clinical trials data strongly support bari-
atric surgery as among the most effective therapeutic
interventions for the treatment of metabolic diseases
in overweight patients.
Regarding mechanisms, bariatric surgery-induced
weight loss is an effective treatment of adiposopathy
(‘‘sick fat’’). As such, understanding the improve-
ment in adipose tissue function with bariatric surgery
is critical towards understanding how and why meta-
bolic diseases are so dramatically improved. In gen-
eral, improved nutrition, increased physical activity
and certain pharmaceuticals consistently improve
adipose tissue endocrine and immune responses
which, in turn, contributes to the improvements in
T2DM, hypertension and dyslipidaemia (13)
(Table 2). Similarly, weight loss from bariatric sur-
gery may (dramatically) improve metabolic disease,
which is a consistent ﬁnding across multiple
clinical trials (18). Therefore, although much
remains to be deﬁned, it is reasonable to conclude
that the fat weight reduction with bariatric surgery
results in anatomic and physiological improvements
in pathogenic adipose tissue, contributing to
improvements in multiple endocrine and immune
responses, which then leads to improvements in met-
abolic disease.
Challenge #2: While bariatric surgery
indication guidelines exist, data are not
always speciﬁc as to who metabolically
beneﬁts most from these procedures
Claim: Currently, the criteria for bariatric surgery are
based on BMI criteria. Bariatric surgery is indicated
for patients with BMI > 40 kg⁄m
2, or > 35 kg⁄m
2 if
associated with obesity-related comorbidities. Under
these current guidelines, patients with BMI <
35 kg⁄m
2 are not candidates for bariatric surgery.
Response: For the morbidly obese patient, weight
loss with bariatric surgery may be helpful to treat
various adverse multiple clinical consequences related
to fat-mass alone, including various cardiovascular,
neurological, pulmonary, musculoskeletal, dermato-
logical, gastrointestinal, genitourinary, renal and psy-
chological diseases (78,79). Additionally, bariatric
surgery prior to pregnancy (or planned pregnancy)
may improve fertility, and may have postpregnancy
maternal and neonatal beneﬁts (80,81).
However, strictly from a metabolic standpoint, not
all overweight or obese patients have evidence of
metabolic disease (82). In fact, some have described
an ‘obesity paradox’ wherein overweight patients
may have some ‘protection’ against the consequences
of metabolic diseases, such as improved outcomes
following atherosclerotic coronary heart disease
(CHD) events (11,83). Conversely, some patients
may have metabolic diseases associated with adipos-
ity, but do not ﬁt the BMI criteria of obesity, such as
sometimes occurs with Asian Indians (1,9,11). Thus,
at least from an endocrine and immune standpoint,
the pathogenic potential of adipose tissue is less
dependent upon the degree of increased fat mass,
but instead more related to the manner in which
positive caloric balance results in ‘sick fat,’ (84) and
the subsequent interactions or ‘cross-talk’ that occurs
between adipose tissue and other body organs (9).
Although the cut-off points for bariatric surgery
are BMI > 40 kg⁄m
2, or > 35 kg⁄m
2 when associated
with comorbidities (85), some data suggest that
bariatric surgery could beneﬁt patients with
adiposopathy and BMI < 35 kg⁄m
2, with signiﬁcant
improvement in metabolic diseases, such as those
with T2DM (86). This is presumably because patho-
genic adipose tissue can contribute to metabolic dis-
ease, even with only mild to modest fat weight gain,
suggesting that adiposopathy might be a more
rational target for treatment of the overweight
patient with metabolic disease than BMI alone (84).
However, the current data available on the metabolic
beneﬁts of bariatric surgery in patients with
BMI < 35 kg⁄m
2 are very limited. So while encour-
aging, more research is needed to more fully examine
the spectrum of patients who might best beneﬁt
from bariatric surgical intervention.
Until selection criteria are better deﬁned for
patients who might additionally beneﬁt from
bariatric surgery based upon their metabolic risk, the
challenge for clinicians is providing access to care for
patients who meet existing criteria for bariatric
surgery. Currently, only 1% of eligible candidates
(based upon existing guidelines) are treated with
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education is needed for clinicians who are in the best
position to refer patients for bariatric surgery, as well
as among obese patients who might potentially
explore this option.
Challenge #3: Bariatric surgery is too risky
compared with other existing treatments
for metabolic disease
Claim: Bariatric surgery is an extreme treatment
option for treating patients with obesity, T2DM,
hypertension and dyslipidaemia and has an unac-
ceptable high degree of morbidity and mortality.
Response: While some healthy overweight and
obese individuals may not be at increased morbidity
or mortality risk, obesity is generally associated with
an increase in overall mortality (88). Multiple clinical
trials demonstrate that bariatric surgery in obese
individual decreases overall mortality compared with
control groups (89–93). Admittedly, the most land-
mark obesity outcomes trials are not randomised
control trials, and thus their interpretation has limi-
tations. However, the totality of data thus far sug-
gests that bariatric surgery is the only method of
intentional weight loss that may save lives, as dem-
onstrated by large controlled clinical trials, conducted
over a long period of time. Regarding safety, as with
all surgical procedures, bariatric surgery does have
risk (Table 1), as do pharmaceutical drug therapies
(94). The degree of risk for bariatric procedures is
not unlike the risks of many other surgical proce-
dures, and is related to the surgical procedure itself
(with gastric bypass having a higher rate of morbid-
ity and mortality compared with LABP) (Table 1) as
well as the expertise of those involved in conducting
the procedure.
In an effort to address the need to maximise the
reduction of surgical risk, ‘Centers of Excellence’
have emerged in an attempt to standardise and
improve the quality of care of bariatric surgery
patients. Recognition as a ‘Center of Excellence’ may
be achieved by undergoing certiﬁcation processes
through the American Society for Metabolic and
Bariatric Surgery and the American College of Sur-
geons (21), and adhering to peri-operative guidelines,
such as those established by the American Associa-
tion of Clinical Endocrinologists, the Obesity Society
and the American Society for Metabolic & Bariatric
Surgery (95). Through the use of experienced surgi-
cal centres, multiple studies of large numbers of
patients reveal that the operative and postoperative
(< 90 days) mortality of the more common bariatric
procedures is < 1%, which is less than many other
surgical procedures (21). This is not to say that bari-
atric surgery is without risk. Acute morbidities occur
in 5–10% of patients, and chronic complications
occur as well (21) (Table 1). This is also not to say
that bariatric surgery is a substitute for appropriate
nutrition and physical activity, which although not
often successful (96), are the safest and the most cost
effective approach to the individual overweight
patient with metabolic disease.
Finally, it is commonplace that rather than treat-
ing the underlying cause of metabolic disease (exces-
sive body fat leading to pathogenic adipose tissue),
clinicians often utilise drug therapies speciﬁc for
individual metabolic diseases that subsequently
emerge in overweight and obese patients. The
approach of treating the consequences of adiposo-
pathy (rather than the cause) does have rationale,
given that many anti-diabetes, anti-hypertensive and
anti-dyslipidaemia agents have well-documented
morbidity and sometimes mortality outcome data
supporting their use. However, while they often
improve metabolic disease, no anti-obesity drug ther-
apy has proved to reduce overall mortality. By con-
trast, bariatric surgery not only often results in
disease remission (21), but multiple studies support
decreased mortality (89–93,97,98). Therefore, in
making the best treatment decision, the patient and
clinician must balance the potential beneﬁts and risks
of non-surgical vs. surgical options in obese patients
with metabolic disease, based upon the best available
data.
Challenge #4: Different bariatric surgery
procedures may have different outcomes
Claim: Bariatric surgical procedures vary, as does the
weight loss following bariatric surgery. These differ-
ences are not always well-known among patients and
clinicians.
Response: Although the discussions of the metabolic
beneﬁts bariatric surgery are often lumped (inappro-
priately) together, different bariatric surgery proce-
dures may have different effects upon adipose tissue
responses. They may therefore have different effects
upon metabolic disease (Tables 1 & 2). In general,
gastric bypass results in greater weight loss than LAGB
over 2 years, with approximation of weight loss
beyond 4 years. Conversely, LAGB has lower short-
term morbidity, although possibly greater reoperation
rates (16). However, as noted earlier, the morbidity
and mortality of all bariatric surgeries are highly
dependent upon who performs the surgery, and where
the procedure is being conducted. Furthermore, any
data regarding the absolute or relative rates of bariat-
ric surgery morbidity and mortality must take into
account the variable of time, in that surgical tech-
niques are constantly advancing towards the relentless
pursuit of improved outcomes (99).
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the speed of initial weight loss and the physiological
changes unique to gastrointestinal diversion may
account for the higher rates of early improvement in
metabolic diseases often observed in gastric bypass
patients, compared with those treated with LAGB (21).
Understanding the potential risk and beneﬁt differ-
ences between common bariatric procedures is impor-
tant for patients and clinicians before considering
surgery to treat metabolic disease. For example, the
potential long-term nutritional deﬁciencies sometimes
associated with gastric bypass need to be balanced
against better shorter term weight loss and reduced
glucose levelsinoverweight patients with T2DM.
Challenge #5: As head-to-head clinical trials
are limited, the short- and long-term safety
and efﬁcacy of bariatric surgery compared
with medical therapies are largely unknown
Claim: While the weight loss achieved with bariatric
surgery is better than with anti-obesity drug therapy
for most patients, isolated patients can achieve sig-
niﬁcant weight loss and weight loss maintenance,
and improvement in metabolic disease with changes
in their nutrition and physical activity, with or
without pharmacotherapy. Furthermore, even
among those who lose weight and have initial
improvement in metabolic disease, many patients
who undergo bariatric surgery regain weight, and
potentially have recurrence of their metabolic dis-
ease status. Thus, little comparative data support
bariatric surgery as a reasonable alternative to medi-
cal therapy in improving metabolic disease in over-
weight patients.
Response: The medical and surgical literature dif-
fers in the convention by which weight loss is
reported. In studies of anti-obesity drug therapies,
weight loss is most often described as the per cent
weight loss, as expressed by a placebo-subtracted
reduction in body weight from the point of ran-
domisation. However, in the surgical literature,
weight loss measurement with bariatric surgery is
often described in terms of ‘excess weight,’ which is
the change in body weight beyond the ideal body
weight. Weight loss divided by ‘excess body weight’
is often reported as the per cent ‘excess weight loss’
or EWL. The EWL reported in bariatric surgery trials
may appear to magnify the results in surgical weight
loss studies if directly compared with what is
reported in medical weight loss studies. Thus, the
distinction between how weight loss is often reported
is necessary to properly compare the efﬁcacy of drug
vs. surgical obesity treatments (100).
Another issue that complicates comparisons of
anti-obesity treatments is that the largest and most
compelling bariatric surgery trials report results in
terms of control group comparisons, and not in
terms of classic randomisation to placebo. This is
because to achieve a true placebo control, sham sur-
gery studies would have to be performed, which are
generally considered unethical, not practical and thus
true placebo-controlled trials are unavailable (101).
Yet other challenges in making efﬁcacy comparisons
include the lack of reporting of absolute data points
(with graphs being displayed instead), and lack of
consistent reporting of month-by-month data time
points. Additionally, weight loss clinical trials have
other intrinsic inherent challenges (102). These chal-
lenges are exacerbated when trying to compare
weight loss efﬁcacy across different therapies because
clinical trials often have substantial differences in
study designs (e.g. some anti-obesity drug trials have
elements of crossover design), variances in placebo
lead-in (in anti-obesity drug trials), variances in the
time of lead-in diet therapies (in anti-obesity drug
trials), different entry populations, different baseline
demographics (the BMI of patients in weight loss
pharmacological trials are often less than the BMI of
patients undergoing bariatric surgery), different
research sites conducting the studies, different
reporting of completers vs. intent to treat, and differ-
ent number⁄percentage of study subject ‘drop outs.’
Regarding the durability of weight loss mainte-
nance, this is one area in which the reported data are
more robust with surgery vs. drug therapy for treat-
ment of obesity. Bariatric surgery has published data
of continued efﬁcacy and reduced mortality data
spanning as long as 10 years (14,89,90). Conversely,
the published literature regarding the long-term efﬁ-
cacy of anti-obesity drug therapy is typically no
longer than 1–2 years (although rare studies have
reported 4-year results) (103). However, a perception
confounder that may affect the clinician’s perspective
is that individual patients may substantially vary in
their maintenance of weight loss with bariatric sur-
gery, as is true with anti-obesity drug therapies.
Other perception confounders are that bariatric sur-
gery ‘‘failures’’ may be remembered more by clini-
cians than successes, and non-surgical obesity
specialists may receive more referrals of bariatric
‘‘failures’’ than bariatric surgery successes.
Finally, some comparative data do support that
treating the underlying cause of metabolic disease
(i.e. adiposity leading to adiposopathy) with bariatric
surgery may be a more effective strategy to improve
metabolic disease, when compared with interventions
directed at treating the consequences of metabolic
disease. At least one study compared LAGB vs. a
multifaceted intensive medical treatment (including
very low calorie diet, anti-obesity pharmacotherapy
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with BMI 30–35 kg⁄m
2. (It is noteworthy that this
entry BMI was below current bariatric surgery guide-
lines.) After 24 months, LAGB was more effective
than non-surgical therapy in reducing weight, reduc-
ing metabolic syndrome and improving quality of life
measurements (15). Many of these same authors also
evaluated overweight T2DM patients with BMI 30–
40 kg⁄m
2, and compared LAGB versus a diabetes
medical team recommendation of lifestyle modiﬁca-
tion (such as appropriate nutrition and physical
activity), with or without other weight loss interven-
tions (such as very low calorie diets and anti-obesity
pharmacological therapies). LAGB achieved greater
weight loss, improved glucose control and induced
greater remission of T2DM than non-surgical, ‘con-
ventional’ diabetes mellitus intervention (15).
Challenge #6: Bariatric surgery may
not be cost effective
Claim: While both might be expected to improve
comorbid conditions, including metabolic diseases,
bariatric surgery is much more expensive than non-
surgical approaches to weight loss and is not cost
effective.
Response: Before addressing the cost of weight loss
treatment, it should be recognised that the cost of a
lack of effective obesity treatment is also substantial
(104). But with regard to treatment, the determina-
tion of what is ‘cost effectiveness’ is dependent upon
the baseline demographic of the patient, the length
of the analysis and the dollar amount per quality-
adjusted life years (QALY). Economic evaluations of
anti-obesity drug therapy (e.g. orlistat, sibutramine
and rimonabant) suggest that such treatments are
generally in the range of what is regarded as ‘cost
effective’ (105). One commonly cited amount
thought to represent cost effectiveness is US $50,000
per QALY (106). Using this ﬁgure, both LAGB and
gastric bypass appear to be cost effective at
< $25,000 each, with LAGB perhaps being more cost
effective than gastric bypass (107). In another analy-
sis of insurance claims with year of index dates rang-
ing from 1 to 6 years, and which assumed the initial
investment for LAGB being $17,000 and the initial
investment for gastric bypass being $26,000, the
health cost savings of bariatric surgery was suggested
to offset the health costs in those not undergoing
surgery after 2 years for laparoscopic surgery and
4 years for open surgery (108). Additional analyses
further support surgically induced weight loss as cost
effective in managing overweight patients with
T2DM (109,110).
In summary, the cost for bariatric surgery is
within the range of ‘cost effectiveness,’ with an
important reason being the reduction in pharmaceu-
tical costs in patients with baseline, drug-treated,
obesity-related comorbidities (111,112). To the
extent that bariatric surgery may not be ‘cost effec-
tive’ for the individual patient who experiences rare
and severe complications, it is perhaps relevant that
some studies suggest that LAGB is associated with
less readmissions after one year compared to gastric
bypass (113) while other studies suggest that gastric
bypass has less incidence of readmission for reopera-
tion (16). These rates are highly variable and depend
on what surgery is performed, where the surgery is
performed, who performs the surgery, the types of
patients who undergo the surgery and are thus
important considerations given that reoperations are
an important determinate regarding long-term cost
effectiveness.
Challenge #7: Patients undergoing bariatric
surgery face ‘continuity of care’ issues that
may compromise their long-term prognosis
Claim: A treatment knowledge gap often exists after
bariatric surgery is performed. It is simply reality
that surgeons are not the clinicians most often
involved in the long-term medical management of
postbariatric surgery patients, their long-term meta-
bolic disease management, or even the needed sur-
veillance of potential long-term complications of
bariatric surgery (Table 1).
Response: The need for the primary care clinician
to assume medical management of the postoperative
surgical patient is a practical and common scenario
in the day-to-day general practice of medicine. For
example, abscess lesions and surrounding cellulitis is
an illustrative example of a ‘sickness’ with a deﬁned
cause (e.g. infection) with potential serious con-
sequences (e.g. inﬂammation and sepsis) that is most
effectively managed surgically (e.g. incision and
drainage) and subsequent medical management (e.g.
antibiotics). The same could be said about CHD
which has a deﬁned cause (the inﬂammatory process
of atherosclerosis) with potential serious conse-
quences (e.g. angina and subsequent myocardial
infarction) that is often managed surgically (e.g. cor-
onary bypass surgery), and subsequent medical
management (e.g. lifestyle and pharmaceutical inter-
vention of multiple metabolic diseases to reduce
future CHD risk).
Similarly, adiposopathy has a deﬁned cause (e.g.
positive caloric balance in environmentally and geneti-
cally susceptible patients) with potential serious con-
sequences (e.g. pathogenic endocrine and immune
processes leading to metabolic disease), that in
many cases, may be most effectively managed surgi-
cally (e.g. bariatric surgery) and subsequent medical
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to treat T2DM, hypertension, dyslipidaemia, etc.).
Unfortunately, many clinicians are far more famil-
iar with the partnership of surgical and medical care
in the patient with a lanced abscess and coronary
artery bypass, than the medical management of the
postbariatric surgery patient. Many clinicians may
not have conﬁdence in their knowledge of the
nuanced efﬁcacy, safety and tolerability differences of
various bariatric surgical procedures, and thus may
not have conﬁdence in their ability to appropriately
recommend bariatric surgery to their patients. Many
may not know how best to follow postbariatric
patients for potential long-term complications
(Table 1). Given that the vast majority of patients
with metabolic diseases are managed by primary care
clinicians and not specialists, then the clinician may
conclude it is best not to refer their overweight
patients for bariatric surgery, in the spirit of primum
non nocere (ﬁrst do no harm). From a practical
standpoint, the development of a new specialisation
in ‘bariatric medicine’ will hopefully help improve
the care of obese patients. However, it is unlikely
that bariatric medicine will overcome the need for
greater awareness and understanding of bariatric sur-
gery by primary care clinicians. Thus, the unfamiliar-
ity of the totality of safety and efﬁcacy issues with
bariatric surgery among clinicians remains a chal-
lenge and potential impediment for the expanded
use of bariatric surgery for patients with adiposopa-
thy and metabolic disease.
It is with this challenge in mind that this review
was written for the purpose of improving clinician
understanding of the improvement in adiposopathy
with bariatric surgery, and the subsequent improve-
ment in metabolic diseases through improvement in
adipose tissue functionality. Other publications and
statements by various governmental and medical
societies provide a more extensive and global discus-
sion of the clinical management aspects of bariatric
surgery as a treatment for severe obesity. Examples
include the US Department of Health and Human
Resources (114) and consensus conference statement
by the American Society for Bariatric Surgery and
the American Society for Bariatric Surgery Founda-
tion (115). Another resource that provides clinical
practice guidelines (CPG) includes the American
Association of Clinical Endocrinologists, The Obesity
Society, and American Society for Metabolic & Bari-
atric Surgery publication entitled: Medical Guidelines
for Clinical Practice for the Perioperative Nutritional,
Metabolic and Non-surgical Support of the Bariatric
Surgery Patient, which states:
‘‘These CPG will focus on the non-surgical aspects of
perioperative management of the bariatric surgery
patient, with special emphasis on nutritional and met-
abolic support’’. The organization of these GPG is as
follows: (i) an Introduction to familiarize the reader
with the principles of bariatric surgery, (ii) a Meth-
ods section to outline the a priori evidence-based
system of recommendations, (iii) an Executive Sum-
mary section of speciﬁc, practical evidence-based rec-
ommendations, (iv) an Appendix section containing
in depth discussion and ratings of the clinical evi-
dence referred to in the Executive Summary of Rec-
ommendations, and lastly (v) an extensive Reference
section in which each clinical report or study is
assigned an evidence level. (22)
Finally, it is the increasing recognition that baria-
tric surgery not only improves the weight of patients,
but also the metabolic health of patients that
prompted the ‘Bariatric Surgical Society’ to change
its name to the ‘American Society for Metabolic &
Bariatric Surgery’ (116). It is also the recognition
that improving the health of patients with bariatric
surgery is largely dependent upon meeting quality
standards that has prompted evidenced-based recom-
mendations for ‘Best Practices’ in weight loss surgery
(117–129).
Challenge #8: Bariatric surgery sends the
‘wrong’ message to obese patients regarding
the importance of needed lifestyle changes
and too many patients consider it a ‘quick ﬁx’
Claim: Society cannot continue to develop, and utilise
risky and expensive interventions to treat what is a
voluntary, lifestyle problem. Bariatric surgery is not
justiﬁed, even in patients who might reasonably be
expected to have improvement in metabolic disease,
because gaining excessive body fat is not because of a
‘disease,’ but rather because of poor personal behav-
iour. By offering bariatric surgery as a treatment
option to overweight patients with metabolic disease,
patients may perceive the clinician as arguing against
appropriate nutrition and physical activity as the most
appropriate ﬁrst step in achieving weight reduction
and in improving their metabolic disease. Improved
nutrition and increase physical activity are far more
appropriate and much more cost effective for individ-
ual overweight patients with metabolic disease.
Response: Bariatric surgery is not a panacea. A
good faith effort at behaviour modiﬁcation, medical
nutritional therapy, appropriate physical activity and
pharmacotherapy should be implemented ﬁrst, with
consideration of bariatric surgery being reserved for
obese patients who have failed medical management.
However, even when indicated, bariatric surgery
should not be considered a ‘cure’ for obesity and
adiposopathy, but rather a tool that will help patients
control their calorie intake with the objective of
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ment of comorbidities. Therefore, prior to recom-
mending bariatric surgery, the clinician should
ensure that the obese patient has undergone thor-
ough screening for the surgical procedures, and edu-
cation about the surgical procedures. After bariatric
surgery, patients need to adhere to appropriate nutri-
tion and physical activity to maximise weight loss
beneﬁts, such as improvements in adipose tissue
function and maintenance of improved metabolic
disease. Patients may also beneﬁt from additional
measures, such as support groups. But even when
obesity is largely caused by poor lifestyle habits, the
withholding of available safe and cost-effective ther-
apy cannot be justiﬁed. This holds true even if the
treatment is surgery – especially among obese
patients with adiposopathy who may be expected to
have substantial improvement, if not remission, in
obesity-related metabolic diseases.
Conclusion
Bariatric surgery is an effective and generally safe
method for the treatment of obesity that often results
in long-term weight loss and improvement and⁄or
remission of metabolic diseases and comorbidities. In
selective obese patients with metabolic disease who
are refractory to medical management, adiposopathy
(‘‘sick fat’’) is a surgical disease.
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